ST2 and CSF-1 as potential druggable targets of inflammatory bowel diseases: Results from two-sample Mendelian randomization study

Serum and synovial fluid levels of CSF-1 and in knee osteoarthritis and its clinical significance

OBJECTIVE

To investigate the serum and synovial fluid levels of CSF-1 in patients with knee osteoarthritis (KOA) and evaluate its clinical significance.

METHODS

We selected 143 patients with KOA who received treatment at our hospital from June 2021 to August 2024. Enzyme-linked immunosorbent assay (ELISA) was used to determine the levels of CSF-1, IL-6, IL-1β, CRP, and HIF-1α in the serum of all study subjects, as well as the levels of these markers in the synovial fluid of all KOA patients. The Kellgren and Lawrence (KL) grading system was used to assess the radiographic severity of all KOA patients. Additionally, we also collected the Visual Analog Scale (VAS) scores and the Western Ontario McMaster University Osteoarthritis Index (WOMAC). Western blot (WB) was used to detect the expression levels of inflammatory factors in macrophages after CSF-1 stimulation.

RESULTS

Compared to healthy volunteers, KOA patients exhibited significantly elevated levels of serum CSF-1, IL-6, IL-1β, CRP, and HIF-1α (p < 0.05). The advanced group of KOA patients had significantly higher levels of serum and synovial fluid CSF-1 compared to the early group. Synovial fluid CSF-1 levels were associated with inflammation and disease severity in KOA patients. CSF-1 stimulation significantly increased the expression of CSF-1R, IL-6, TNF-α, IL-1β, HIF-1α, and MMP-3 in macrophages. Moreover, synovial fluid and serum CSF-1, synovial fluid HIF-1α, and synovial fluid IL-6 were identified as risk factors for advanced KOA.

CONCLUSION

Our findings indicated that the serum and synovial fluid levels of CSF-1 were significantly increased in KOA patients, even higher in patients with KL grade 3-4. Moreover, CSF-1 was identified as a risk factor associated with advanced stage KOA.

Protein-centric omics integration analysis identifies candidate plasma proteins for multiple autoimmune diseases

It remains challenging to translate the findings from genome-wide association studies (GWAS) of autoimmune diseases (AIDs) into interventional targets, presumably due to the lack of knowledge on how the GWAS risk variants contribute to AIDs. In addition, current immunomodulatory drugs for AIDs are broad in action rather than disease-specific. We performed a comprehensive protein-centric omics integration analysis to identify AIDs-associated plasma proteins through integrating protein quantitative trait loci datasets of plasma protein (1348 proteins and 7213 individuals) and totally ten large-scale GWAS summary statistics of AIDs under a cutting-edge systematic analytic framework. Specifically, we initially screened out the protein-AID associations using proteome-wide association study (PWAS), followed by enrichment analysis to reveal the underlying biological processes and pathways. Then, we performed both Mendelian randomization (MR) and colocalization analyses to further identify protein-AID pairs with putatively causal relationships. We finally prioritized the potential drug targets for AIDs. A total of 174 protein-AID associations were identified by PWAS. AIDs-associated plasma proteins were significantly enriched in immune-related biological process and pathways, such as inflammatory response (P = 3.96 × 10-10). MR analysis further identified 97 protein-AID pairs with potential causal relationships, among which 21 pairs were highly supported by colocalization analysis (PP.H4 > 0.75), 10 of 21 were the newly discovered pairs and not reported in previous GWAS analyses. Further explorations showed that four proteins (TLR3, FCGR2A, IL23R, TCN1) have corresponding drugs, and 17 proteins have druggability. These findings will help us to further understand the biological mechanism of AIDs and highlight the potential of these proteins to develop as therapeutic targets for AIDs.

Mendelian randomisation analysis for intestinal disease: achievement and future

Intestinal disease is a group of complex digestive system diseases imposing a significant burden globally. Identifying the risk factors and potential complications of intestinal disease is important for its prevention and treatment. However, traditional observational clinical studies are limited by confounding factors and reverse causation, making causal inference challenging. Mendelian randomisation (MR) method has been developed to effectively mitigate these constraints and assess the causal relationships. This review briefly introduces the MR method, summarises MR research on intestinal disease and delineates the prospective avenues for future research. Conventional risk factors, such as lifestyle behaviours (eg, physical activity, smoking and alcohol consumption), nutrients (eg, selenium), obesity markers (eg, body mass index and waist-to-hip ratio) and inflammatory biomarkers, have been validated in MR studies. Multiomics MR studies are becoming novel hotspots, which provide a theoretical foundation for the exploration of pathogenesis and the investigation of new drug targets. However, most of the recent studies are based on European individuals, and thus it is necessary to replicate the results in other ancestries. Moreover, triangulation integrating MR and other epidemiology methods is suggested as a validated paradigm for causal inference in future MR studies.